Phase II High-Dose Cyclophosphamide for Multiple Sclerosis
Status:
Withdrawn
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine what percentage of patients receiving high-dose
Cyclophosphamide may experience a halt in the worsening of their disease or experience
improvement of their disease and for how long the benefit may last.